Finerenone in Patients with CKD and T2D by SGLT2i Treatment: An Analysis of the FIDELIO-DKD Study

被引：0
|
作者：
Rossing, Peter
Agarwal, Rajiv
Anker, Stefan
Filippatos, Gerasimos
Pitt, Bertram
Ruilope, Luis M.
Chan, Juliana C.
Kooy, Adriaan
Mccafferty, Kieran
Schernthaner, Guntram
Wanner, Christoph
Joseph, Amer
Scheerer, Markus F.
Scott, Charlie
Bakris, George
机构：
来源：
DIABETES | 2021年 / 70卷
关键词：
D O I：
10.2337/db21-14-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
14-LB
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Influence of SGLT2I on tubulointerstitium in DKD patients with moderate renal dysfunction
    Murakami, Keisuke
    Kato, Sawako
    Sugaya, Takeshi
    Kuwatsuka, Yachiyo
    Ando, Masahiko
    Maruyama, Shoichi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I110 - I111
  • [22] Finerenone Dose-Exposure-UACR Response Analyses of FIDELIO-DKD Phase 3 and the Effect of SGLT-2 Inhibitor Co-Medication
    Heerspink, Hiddo J. L.
    Goulooze, Sebastiaan
    van Noort, Martijn
    Snelder, Nelleke
    Brinker, Meike D.
    Lippert, Joerg
    Eissing, Thomas
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2021, 32 (10): : 262 - 262
  • [23] Influence of SGLT2I on tubulointerstitium in DKD patients with moderate renal dysfunction
    Murakami, Keisuke
    Kato, Sawako
    Sugaya, Takeshi
    Kuwatsuka, Yachiyo
    Ando, Masahiko
    Maruyama, Shoichi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [24] Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study
    Rossing, Peter
    Burgess, Ellen
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Gillard, Pieter
    MacIsaac, Richard J.
    Wainstein, Julio
    Joseph, Amer
    Brinker, Meike
    Roessig, Lothar
    Scott, Charlie
    Bakris, George L.
    DIABETES CARE, 2022, 45 (04) : 888 - 897
  • [25] FINERENONE AND CANAGLIFLOZIN IN THE TREATMENT OF CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: MATCHING-ADJUSTED INDIRECT TREATMENT COMPARISON OF FIDELIO-DKD AND CREDENCE
    Cherney, David
    Folkerts, Kerstin
    Mernagh, Paul
    Nikodem, Mateusz
    Pawlitschko, Joerg
    Rossing, Peter
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2022, 37 : I848 - I849
  • [26] Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial
    Rossing, Peter
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Ruilope, Luis M.
    Amod, Aslam
    Marre, Michel
    Joseph, Amer
    Lage, Andrea
    Scott, Charlie
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (01): : 125 - 134
  • [27] SGLT2i Treatment Reduces Cardiorenal Disease Risk in T2D Patients Without Established Cardiovascular and Renal Diseases: A Large Observational Study
    Komuro, Issei
    Bodegard, Johan
    Thuresson, Marcus
    Yajima, Toshitaka
    Eriksson, Jan W.
    Norhammar, Anna
    Birkeland, Kare I.
    Kadowaki, Takashi
    CIRCULATION, 2019, 140 (25) : E980 - E980
  • [28] Level of Glycemic Control in Type 2 Diabetes (T2D) Patients with Established Cardiovascular Disease (eCVD) or Chronic Kidney Disease (CKD) Prescribed an SGLT2i
    Iglay, Kristy
    Bansal, Neha
    Gulati, Tania
    Hannachi, Hakima
    Fernandes, Gail
    Rajpathak, Swapnil
    DIABETES, 2019, 68
  • [29] EFFECTS OF FINERENONE ON CARDIORENAL OUTCOMES IN BLOOD PRESSURE SUBGROUPS IN PATIENTS WITH CKD AND T2D
    Ruilope, Luis
    Agarwal, Rajiv
    Anker, Stefan D.
    Filippatos, Gerasimos
    Pitt, Bertram
    Rossing, Peter
    Sarafidis, Pantelis
    Schmieder, Roland E.
    Joseph, Amer
    Mentenich, Nicole
    Nowack, Christina
    Bakris, George
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [30] SGLT2I AS RENOPROTECTION TOOL IN CHILDREN WITH CKD
    Ivanov, Dmytro
    Ivanova, Mariia
    PEDIATRIC NEPHROLOGY, 2021, 36 (10) : 3325 - 3325
12345